Add BrightSurf on Google Email

EMBARGOED: Targeting enzyme could alleviate muscle wasting for cancer patients

Researchers have identified a key enzyme in muscle that contributes to cancer-induced muscle wasting. Targeting this enzyme, UBR2, may help preserve muscle mass and function in cancer patients. The study's findings offer new hope for the treatment of cancer cachexia, a complication affecting 60% of all cancer patients.

SourceUniversity of Texas Health Science Center at Houston·JournalProceedings of the National Academy of Sciences·DateOct 17, 2022

Pitt-developed genetic test for pancreatic cancer outperforms current guidelines

A new genetic test called PancreaSeq accurately classifies pancreatic cysts as potentially cancerous or benign, improving the accuracy of diagnoses compared to current guidelines. The test distinguishes between different types of cysts with higher accuracy than traditional forms of surveillance and current pancreatic cyst guidelines.

SourceUniversity of Pittsburgh·JournalGastroenterology·TypeObservational study·DateOct 5, 2022

Researchers develop a new surgical training model for fluorescence-guided cancer surgery using the Japanese food konjac jelly

A team of researchers at Nagoya University has developed a novel tissue-mimicking phantom using konjac, enabling surgeons to practice fluorescence-guided cancer surgery. The model's use of indocyanine green and konjac jelly makes it suitable for training with electrocautery, promoting safer and more reliable surgical techniques.

SourceNagoya University·JournalLaryngoscope Investigative Otolaryngology·DateSep 30, 2022

Modelling the use of Beta Radiation in cancer treatment

Researchers compare Monte Carlo simulations and Loevinger formula for beta radiation dosimetry in cancer treatment, finding the latter to be a quick yet accurate method. The study suggests using the Loevinger formula as a basis for dosimetry software in simple geometries.

SourceSpringer·JournalThe European Physical Journal Plus·DateSep 29, 2022

Machine learning creates opportunity for new personalized therapies

Researchers developed a computational platform to identify metabolic vulnerabilities in ovarian cancer genes, suggesting opportunities for targeted therapies. The study found that certain genetic alterations can create vulnerabilities in cancer cell metabolism, which can be exploited to selectively kill cancer cells.

SourceMichigan Medicine - University of Michigan·JournalNature Metabolism·TypeExperimental study·DateSep 28, 2022

Colonoscopies in FIT-positive persons requires much higher ADR than primary colonoscopy

A cohort study found that endoscopists performing colonoscopies in FIT-based screening programs should aim for markedly higher ADRs compared to primary colonoscopy screening. The study suggests that high ADRs are associated with lower colorectal cancer incidence and mortality. Researchers recommend using ADR targets, including differen...

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeObservational study·DateSep 26, 2022

St. Jude finds a new way to identify ‘safe harbor’ for gene therapies

Scientists at St. Jude Children's Research Hospital have created a tool to identify 'safe harbor' sites for gene therapies, balancing safety and therapeutic expression. The tool uses genomic and epigenetic information to find regions with high variability among healthy individuals, reducing the risk of cancer or other problems.

SourceSt. Jude Children's Research Hospital·JournalGenome Biology·TypeExperimental study·DateSep 22, 2022

New study in JNCCN suggests way to predict outcomes with high accuracy prior to surgery for pancreatic cancer patients

Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateSep 8, 2022

Moffitt physicians lead international study to identify melanoma patients with high-risk disease

Researchers identified high-risk patients with stage 3A disease and microscopic lymph node metastases who would benefit from adjuvant therapy. Patients with larger metastases had poorer outcomes, while those with smaller metastases had better survival rates similar to stage 1A disease.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalJournal of Clinical Oncology·TypeMeta-analysis·DateAug 23, 2022

Mechanistic insights into contact hypersensitivity could pave the way for drug discovery

A study by Japanese researchers from Fujita Health University sheds light on the molecular mechanisms of contact dermatitis, revealing that neutrophil extracellular traps play a key role in the condition. The team's findings suggest that inhibiting NET formation could be a new therapeutic strategy for treating contact dermatitis.

SourceFujita Health University·JournalScientific Reports·TypeExperimental study·DateAug 17, 2022

Oncotarget | Kinase activity in renal cell carcinoma, benign renal tissue and in response to tyrosine kinase inhibitors

Researchers identified differences in PTK activity between normal and cancer kidney tissue, with Src family kinases and PI3K pathways exhibiting high activity. Ex vivo treatment of clear cell RCC with TKIs revealed that tivozanib and cabozantinib were more potent inhibitors than sunitinib or pazopanib.

SourceImpact Journals LLC·JournalOncotarget·TypeData/statistical analysis·DateAug 17, 2022

Oncotarget | Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

Researchers investigated the effects of neoadjuvant chemoradiotherapy on CD8+ tumor-infiltrating lymphocytes, PD-L1, and mucin expression in rectal cancer patients. The study found that nCRT exposure was associated with higher mucin expression and a non-significant difference in PD-L1 expression, suggesting an immunosuppressive phenotype.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateAug 2, 2022

ACP offers guidance on the ethical use of genetic testing and precision medicine

The American College of Physicians (ACP) has issued a position paper on the ethical use of genetic testing and precision medicine in internal medicine. The guidelines address key issues such as incidental findings, education for physicians and patients, and counseling needs. ACP emphasizes the need for ongoing surveillance and anticoag...

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeLiterature review·DateJul 25, 2022

People with early-stage Hodgkin lymphoma face a higher risk of dying from cardiovascular disease than from cancer

A recent study published in CANCER highlights the growing concern among Hodgkin lymphoma survivors. The analysis found that individuals with early-stage HL are now at a higher risk of death from cardiovascular disease compared to cancer after approximately 60 and 120 months of follow-up. This indicates that more effective measures are ...

SourceWiley·JournalCancer·DateJul 25, 2022

CRISPR therapeutics can damage the genome

A new study from Tel Aviv University found that CRISPR therapeutics can lead to a significant loss of genetic material in treated cells, potentially destabilizing the genome and promoting cancer. The researchers detected up to 10% of cells with lost chromosomes, highlighting the need for extra care when using this technology.

SourceTel-Aviv University·JournalNature Biotechnology·DateJul 24, 2022

Hormone replacement therapy doesn't lead to breast cancer reoccurrence

A large cohort study found that hormone replacement therapy for breast cancer survivors is not associated with an increased risk of recurrence. The study included over 8,400 Danish postmenopausal women and found no link between vaginal estrogen or menopausal hormone therapy and breast cancer reoccurrence.

SourceOxford University Press USA·JournalJNCI Journal of the National Cancer Institute·TypeData/statistical analysis·DateJul 20, 2022

New AI model for the accurate diagnosis of neoplasia associated with inflammatory bowel disease

Researchers developed an AI system that classifies IBDN lesions accurately, displaying image-based diagnostic ability with 64.5% sensitivity and 89.5% specificity. The correct diagnosis rate of the AI system was 79.0, surpassing that of endoscopists, who achieved a 77.8% accuracy rate.

SourceOkayama University·JournalJournal of Gastroenterology and Hepatology·TypeComputational simulation/modeling·DateJul 13, 2022